All studies involving LG/J


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Benavides1 genotype assessment Gpr84 allele assessment. PCR, sequencing. None None inbred w/CC8   (58) both 6wks 2013
Berndt1 ventilator
with methacholine
Airway resistance. Baseline vs. methacholine-challenged (several doses). None MCh inbred   (37) both 9-12wks 2010
Bopp1 health assessment
with Plasmodium berghei
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. None None inbred   (31) both 8-12wks 2010
Broad2 genotyping SNP profiling, 131,000+ genomic locations, 1-19,X. None SNPs inbred   (89) 2009
CGD-MDA1 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. None SNPs inbred   (142) m 2014
CGDpheno1 body size and weight Body weight and length. None BW inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. Cell counts, white cells, lymphocytes, neutrophils, monocytes, eosinophils, red cell parameters, hemoglobin, hematocrit, reticulocytes, platelets CBC, RBC, WBC, CHCM, EOS, HCT, HGB, LYM, MCH, MCHC, MONO, MPV, NEUT, PLT, RET, RETIC inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 DXA Body mass, fat mass, lean mass, bone mineral density. None BMD inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. None CHOL, FFA, TG inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. glucose, bilirubin, urea nitrogen, thyroxine, chloride, potassium, sodium, dissolved carbon dioxide BIL, CO2, GLU, T4, TBIL, chem inbred w/CC8   (72) both 10-13wks 2009
Cheverud1 body weight
with high-fat diet
Body weight and growth curve from age 1wk to 22wks (pre-wean, post-wean, adult). High-fat diet (17wks) vs. control. None BW LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 fat pad weights
with high-fat diet
High-fat diet (17wks) vs. control. gonadal, perirenal, mesenteric, inguinal, total None LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 glucose tolerance
with high-fat diet
High-fat diet (17wks) vs. control. 0 to 120 min after 10% glucose i.p. 4h fast. None GLU, GTT LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 hormone quantification
with high-fat diet
Insulin, leptin. None INS, LEP LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 lipid profile
with high-fat diet
Cholesterol, triglycerides, free fatty acids. High-fat diet (17wks) vs. control. 4h fast, serum. None CHOL, FFA, TG LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 organ weights
with high-fat diet
Heart, liver, kidney, spleen weights after high-fat diet (17wks) vs. control. None None LGXSM w/par   (19) both 12-16wks 2004
Hadsell1 body weight Daily body weight gain of cross-fostered pups. None BW inbred   (31) f 14-18wks 2012
Hadsell1 colony observation Maternal nurturing study. Number of pups, survival and weight gain of pups. None inbred   (31) f 14-18wks 2012
Harrill1 body weight
with isoniazid
Body weight. Isoniazid-treated vs. control. None None inbred   (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid
Liver pathology scores. Isoniazid-treated vs. control. lymphohistiocytic, hepatocytic None inbred   (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. None CHOL, TG inbred   (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid
Alanine transaminase. Isoniazid-treated vs. control. alanine transaminase ALT inbred   (34) f 8-10wks 2011
Harrill1 organ weights
with isoniazid
Body, liver, kidney weights. Isoniazid-treated vs. control. None None inbred   (34) f 8-10wks 2011
Harrill2 biomarker quantification
with DB289
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. None KIM-1, KIM1 inbred   (34) f 6-8wks 2012
Harrill2 body weight
with DB289
DB289-treated vs. control. None BW inbred   (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289
Kidney metabolite (DB75) concentration. DB289-treated vs. control. None None inbred   (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. None ALT, BUN, CREA inbred   (34) f 6-8wks 2012
Harrill2 organ weights
with DB289
Kidney and liver weights. DB289-treated vs. control. None LW inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289
Urine volume, creatinine. DB289-treated vs. control. kidney CREA inbred   (34) f 6-8wks 2012
Haston1 bronchoalveolar lavage assessment
with radiation
Bronchoalveolar cell differential after exposure to radiation (18 Gy). macrophages, lymphocytes, neutrophils, cytospin centrifuge LYM, NEUT inbred   (26) both 15-36wks 2012
Haston1 health assessment
with radiation
Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). None None inbred   (26) both 15-36wks 2012
Haston1 histopathology
with radiation
Post exposure to radiation. mast cells, inflammation index None inbred   (26) both 15-36wks 2012
HMDPpheno10 metabolite quantification Liver metabolic profiling. Molecular measures of nucleotides, peptides. 16h fast. None None HMDP   (106) m 16wks 2014
HMDPpheno2 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. None CHOL, FFA, TG HMDP   (99) m 16wks 2010
HMDPpheno2 NMR Percent fat. None None HMDP   (99) m 16wks 2010
HMDPpheno3 tail cuff Heart rate and blood pressure. Conscious mice. None BP, HR HMDP   (58) m 9-10wks 2012
HMDPpheno4 fear conditioning test Contextual fear, cued fear. None FC HMDP   (94) m 10wks 2011
HMDPpheno5 complete blood count Hematology. cell counts, white cells, lymphocytes, monocytes, granulocytes, red cell parameters, hemoglobin, hematocrit reticulocytes, platelets CBC, RBC, WBC, CHCM, HCT, HGB, LYM, MCH, MCHC, MONO, MPV, PLT, RET, RETIC HMDP   (83) m 16wks 2013
HMDPpheno6 metabolite quantification Liver metabolic profiling. Molecular measures of amino acids. 16h fast. None None HMDP   (106) m 16wks 2014
HMDPpheno7 metabolite quantification Liver metabolic profiling. Molecular measures of carbs, cofactors, vitamins, energy, xenobiotics. 16h fast. None None HMDP   (106) m 16wks 2014
HMDPpheno8 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (non-lysolipids). 16h fast. None None HMDP   (106) m 16wks 2014
HMDPpheno9 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (lysolipids). 16h fast. None None HMDP   (106) m 16wks 2014
Johnson1 ABR test Auditory brainstem response. None ABR inbred   (51) both 3-12wks and 15-72wks 2000
Lightfoot1 body weight Body weight None BW inbred   (41) both 8-9wks 2010
Lightfoot1 running wheel monitoring Distance, duration, speed. None None inbred   (41) both 8-9wks 2010
Mogil3 nociception assay von Frey nociception test, baseline and after spared nerve injury (SNI) surgery as a hypersensitizer. None None inbred   (18) both 7-12wks 2012
Pletcher1 body weight Body weight None BW inbred   (32) m 7-9wks 2007
Pletcher1 hormone quantification Corticosterone (serum). None None inbred   (32) m 7-9wks 2007
Pletcher1 open field test Locomotor and anxiety-related behavior. 7 min test. None OFT inbred   (32) m 7-9wks 2007
Pletcher1 tail suspension test Immobility percentage. immobility percentage, hopelessness, depression TST inbred   (32) m 7-9wks 2007
Sandell1 health assessment Post-injury wound healing. Ear cartilage and articular cartilage. None None LGXSM w/par   (15) both 6-7wks 2012
Sandell1 histopathology Post-injury wound healing. Articular cartilage at 12wks and 16wks post-injury. None None LGXSM w/par   (15) both 6-7wks 2012
Tarantino1 body weight
with cocaine
Body weight None BW inbred   (45) m 8-11wks 2015
Tarantino1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. None OFT inbred   (45) m 8-11wks 2015
Tarantino2 forced swim test
with ovariectomy
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. immobility time, hopelessness, depression None inbred   (37) f 8-10wks 2016
Tarantino2 open field test
with ovariectomy
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. None OFT inbred   (37) f 8-10wks 2016
UCLA1 genotyping SNP profiling, 132,000+ genomic locations, 1-19,X None SNPs HMDP   (248) both 2018
Vulpe1 mineral quantification Liver mineral levels. Iron, copper, zinc. Iron homeostasis. None None inbred   (18) both 8wks 2010
Vulpe1 transferrin quantification Diferric transferrin (plasma). None None inbred   (18) both 8wks 2010
Wiltshire1 elevated plus maze Locomotor activity. None EPM inbred   (38) both 12-14wks 2010
Wiltshire1 light-dark box Light-dark test. Anxiety-related behavior. None None inbred   (38) both 12-14wks 2010
Wiltshire1 open field test Locomotor activity. None OFT inbred   (38) both 12-14wks 2010
Wiltshire2 drug and metabolite quantification
with fluoxetine
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. None None inbred   (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. None OFT inbred   (30) m 9-11wks 2011
Wiltshire2 tail suspension test
with fluoxetine
Immobility. Fluoxetine-treated vs. control. 5 min test. immobility time, hopelessness, depression TST inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. cerebral cortex None inbred   (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with cancer drugs
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. B cells, T cells, monocytes, IC50 MONO inbred w/CC7   (36) m 10wks 2015